Kouji Joko

List of Publications by Year
in descending order

54 papers	1,807 citations	279487 23 h-index	288905 40 g-index
54 all docs	54 docs citations	54 times ranked	1683 citing authors

#	Article	IF	Citations
1	Albumin-Bilirubin (ALBI) Grade as Part of the Evidence-Based Clinical Practice Guideline for HCC of the Japan Society of Hepatology: A Comparison with the Liver Damage and Child-Pugh Classifications. Liver Cancer, 2017, 6, 204-215.	4.2	159
2	Validation of Modified ALBI Grade for More Detailed Assessment of Hepatic Function in Hepatocellular Carcinoma Patients: A Multicenter Analysis. Liver Cancer, 2019, 8, 121-129.	4.2	159
3	Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in realâ€world conditionsâ€”Multicenter analysis. Cancer Medicine, 2019, 8, 3719-3728.	1.3	131
4	Hepatic Function during Repeated TACE Procedures and Prognosis after Introducing Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: Multicenter Analysis. Digestive Diseases, 2017, 35, 602-610.	0.8	113
5	Clinical features of lenvatinib for unresectable hepatocellular carcinoma in realâ€world conditions: Multicenter analysis. Cancer Medicine, 2019, 8, 137-146.	1.3	112
6	Therapeutic potential of lenvatinib for unresectable hepatocellular carcinoma in clinical practice: Multicenter analysis. Hepatology Research, 2019, 49, 111-117.	1.8	81
7	Important Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular Carcinoma. Oncology, 2019, 97, 277-285.	0.9	66
8	Predictors of hepatocellular carcinoma occurrence after directâ€acting antiviral therapy in patients with hepatitis C virus infection. Hepatology Research, 2019, 49, 136-146.	1.8	54
9	Neutrophilâ€toâ€lymphocyte ratio is associated with survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib. Liver International, 2020, 40, 968-976.	1.9	51
10	Lenvatinib versus sorafenib in firstâ€line treatment of unresectable hepatocellular carcinoma: An inverse probability of treatment weighting analysis. Liver International, 2021, 41, 1389-1397.	1.9	45
11	Safety and efficacy of lenvatinib in elderly patients with unresectable hepatocellular carcinoma: A multicenter analysis with propensity score matching. Hepatology Research, 2020, 50, 75-83.	1.8	44
12	Does interferon-free direct-acting antiviral therapy for hepatitis C after curative treatment for hepatocellular carcinoma lead to unexpected recurrences of HCC? A multicenter study by the Japanese Red Cross Hospital Liver Study Group. PLoS ONE, 2018, 13, e0194704.	1.1	41
13	Impact of albuminâ€“bilirubin grade on survival in patients with hepatocellular carcinoma who received sorafenib: An analysis using timeâ€dependent receiver operating characteristic. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 1066-1073.	1.4	40
14	Early Relative Change in Hepatic Function with Lenvatinib for Unresectable Hepatocellular Carcinoma. Oncology, 2019, 97, 334-340.	0.9	39
15	Post-Progression Treatment Eligibility of Unresectable Hepatocellular Carcinoma Patients Treated with Lenvatinib. Liver Cancer, 2020, 9, 73-83.	4.2	37
16	Complex Pattern of Resistance-Associated Substitutions of Hepatitis C Virus after Daclatasvir/Asunaprevir Treatment Failure. PLoS ONE, 2016, 11, e0165339.	1.1	36
17	Real-world efficacy and safety of ledipasvir and sofosbuvir in patients with hepatitis C virus genotype 1 infection: a nationwide multicenter study by the Japanese Red Cross Liver Study Group. Journal of Gastroenterology, 2018, 53, 1142-1150.	2.3	36
18	Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Childâ€Pugh class A or B liver function in realâ€world clinical practice. Hepatology Research, 2022, 52, 773-783.	1.8	34

#	Article	IF	Citations
19	Lenvatinib versus Sorafenib as firstâ€line treatment in hepatocellular carcinoma: A multiâ€institutional matched caseâ€control study. Hepatology Research, 2021, 51, 1229-1241.	1.8	33
20	Clinical importance of muscle volume in lenvatinib treatment for hepatocellular carcinoma: Analysis adjusted with inverse probability weighting. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 1812-1819.	1.4	28
21	Realâ€world efficacy and safety of sofosbuvir + ribavirin for hepatitis C genotype 2: A nationwide multicenter study by the Japanese Red Cross Liver Study Group. Hepatology Research, 2019, 49, 264-270.	1.8	27
22	Neutrophilâ€“lymphocyte ratio predicts early outcomes in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: a multicenter analysis. European Journal of Gastroenterology and Hepatology, 2022, 34, 698-706.	0.8	27
23	Comparison of standard-dose and half-dose sorafenib therapy on clinical outcome in patients with unresectable hepatocellular carcinoma in field practice: A propensity score matching analysis. International Journal of Oncology, 2014, 45, 2295-2302.	1.4	26
24	Risk of hepatocellular carcinoma in cirrhotic hepatitis <scp>B</scp> virus patients during nucleoside/nucleotide analog therapy. Hepatology Research, 2015, 45, 872-879.	1.8	26
25	Using ALBI score at the start of sorafenib treatment to predict regorafenib treatment candidates in patients with hepatocellular carcinoma. Japanese Journal of Clinical Oncology, 2019, 49, 42-47.	0.6	25
26	Direct-acting antivirals improve survival and recurrence rates after treatment of hepatocellular carcinoma within the Milan criteria. Journal of Gastroenterology, 2021, 56, 90-100.	2.3	25
27	Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLCâ€B stage patients classified as beyond up to seven criteria â€“ Multicenter analysis. Hepatology Research, 2022, 52, 308-316.	1.8	25
28	Does firstâ€line treatment have prognostic impact for unresectable <scp>HCC</scp>?â€”Atezolizumab plus bevacizumab versus lenvatinib. Cancer Medicine, 2023, 12, 325-334.	1.3	25
29	Change in Fibrosis 4 Index as Predictor of High Risk of Incident Hepatocellular Carcinoma After Eradication of Hepatitis C Virus. Clinical Infectious Diseases, 2021, 73, e3349-e3354.	2.9	21
30	Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib. Liver International, 2021, 41, 2997-3008.	1.9	18
31	Association of early bevacizumab interruption with efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: A landmark analysis. Hepatology Research, 2022, 52, 462-470.	1.8	18
32	Realâ€world efficacy of elbasvir and grazoprevir for hepatitis C virus (genotype 1): A nationwide, multicenter study by the Japanese Red Cross Hospital Liver Study Group. Hepatology Research, 2019, 49, 1114-1120.	1.8	17
33	Prospective cohort trial to confirm the efficacy of noâ€touch radio frequency ablation. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 567-574.	1.4	16
34	Realâ€world clinical outcomes of sofosbuvir and velpatasvir treatment in HCV genotype 1â€and 2â€infected patients with decompensated cirrhosis: A nationwide multicenter study by the Japanese Red Cross Liver Study Group. Journal of Medical Virology, 2021, 93, 6247-6256.	2.5	16
35	Effects of long-term entecavir treatment on the incidence of hepatocellular carcinoma in chronic hepatitis B patients. Hepatology International, 2016, 10, 320-327.	1.9	15
36	Therapeutic efficacy of lenvatinib as thirdâ€line treatment after regorafenib for unresectable hepatocellular carcinoma progression. Hepatology Research, 2021, 51, 880-889.	1.8	15

#	Article	IF	Citations
37	Multipolar versus monopolar radiofrequency ablation for hepatocellular carcinoma in the caudate lobe: Results of a propensity score analysis. Hepatology Research, 2017, 47, 658-667.	1.8	13
38	Impact of modified albuminâ€“bilirubin grade on survival in patients with HCC who received lenvatinib. Scientific Reports, 2021, 11, 14474.	1.6	13
39	Effects of antiviral therapy for hepatitis C following treatment of hepatocellular carcinoma: survey findings of the Japanese Red Cross Liver Study Group. Hepatology Research, 2016, 46, 251-258.	1.8	12
40	Role of severe thrombocytopenia in preventing platelet count recovery in thrombocytopenic patients with chronic liver disease. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 299-304.	1.4	12
41	What Can Be Done to Solve the Unmet Clinical Need of Hepatocellular Carcinoma Patients following Lenvatinib Failure?. Liver Cancer, 2021, 10, 115-125.	4.2	12
42	Efficacy of daclatasvir plus asunaprevir in patients with hepatitis C virus infection undergoing and not undergoing hemodialysis. Hepatology Research, 2018, 48, 746-756.	1.8	11
43	AFP and eGFR are related to early and late recurrence of HCC following antiviral therapy. BMC Cancer, 2021, 21, 699.	1.1	10
44	Hepatocellular Carcinoma Risk Assessment for Patients With Advanced Fibrosis After Eradication of Hepatitis C Virus. Hepatology Communications, 2022, 6, 461-472.	2.0	10
45	Sex difference in the development of hepatocellular carcinoma after directâ€acting antiviral therapy in patients with HCV infection. Journal of Medical Virology, 2020, 92, 3507-3515.	2.5	9
46	Efficacy and safety of glecaprevir/pibrentasvir as retreatment therapy for patients with genotype 2 chronic hepatitis C who failed prior sofosbuvir plus ribavirin regimen. Hepatology Research, 2019, 49, 1121-1126.	1.8	8
47	Real-World Data on Ramucirumab Therapy including Patients Who Experienced Two or More Systemic Treatments: A Multicenter Study. Cancers, 2022, 14, 2975.	1.7	5
48	A validation study of after directâ€acting antivirals recommendation for surveillance score for the development of hepatocellular carcinoma in patients with hepatitis C virus infection who had received directâ€acting antiviral therapy and achieved sustained virological response. JGH Open, 2022, 6, 20-28.	0.7	4
49	C-reactive protein to albumin ratio predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib. Scientific Reports, 2022, 12, 8421.	1.6	4
50	Glasgow prognostic score predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib: a multicenter analysis. European Journal of Gastroenterology and Hepatology, 2022, 34, 857-864.	0.8	3
51	Successful splenorenal shunt occlusion with balloonâ€occluded retrograde transvenous obliteration yielded improvement of residual liver function, enabled administration of directâ€acting antivirals, and achieved sustained virological response to hepatitis <scp>C</scp> virus: <scp>A</scp> case report. Journal of Digestive Diseases, 2017, 18, 125-129.	0.7	0
52	Relation of Reduction of Antibodies against Hepatitis B Virus to Hepatocellular Carcinoma Recurrence in the Patients with Resolved Hepatitis B Virus Infection Following Direct-acting Antiviral Therapy for Hepatitis C Virus Infection. Euroasian Journal of Hepato-gastroenterology, 2019, 9, 78-83.	0.1	0
53	Efficacy of hepatitis C virus eradication after curative treatment for hepatocellular carcinoma in patients with advanced hepatocellular carcinoma and decreased hepatic functional reserve: A nationwide, multicenter study by the Japanese Red Cross Liver Study Group. Journal of Viral Hepatitis, 2022, . .	1.0	0
54	<scp>General evaluation score</scp> for predicting the development of <scp>hepatocellular carcinoma</scp> in patients with advanced liver fibrosis associated with <scp>hepatitis C virus</scp> genotype 1 or 2 after <scp>directâ€acting antiviral</scp> therapy. JGH Open, 2022, 6, 487-495.	0.7	0